surmount-1 tirzepatide Presented today at #ECO2026 ⤵️ The SURMOUNT-MAINTAIN trial found that continuing at the maximum tolerated dose maintained bodyweight reduction and health-related benefits in adults with obesity. Explore the research: https://t.co/RjLxWa5qjV SURMOUNT-1 Trial - Cardionerds Twitter
Description
In October 2024, the FDA determined that the tirzepatide injection shortage had been resolved
Step-by-Step Reconstitution Guide Mixing medication requires a clean environment and a steady hand
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial
Do not twist or jiggle the needle during removal
While semaglutide or tirzepatide can be very effective for weight loss, they should not be combined
